292 related articles for article (PubMed ID: 16480430)
1. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
Nachbaur D; Clausen J; Kircher B
Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
[TBL] [Abstract][Full Text] [Related]
2. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
Nachbaur D; Larcher C; Kircher B; Eibl G; Nussbaumer W; Gunsilius E; Haun M; Grünewald K; Gastl G
Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
5. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Yamaguchi T; Tojo A; Asano S
Eur J Haematol; 2008 Mar; 80(3):251-7. PubMed ID: 18081702
[TBL] [Abstract][Full Text] [Related]
6. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
Uzunel M; Remberger M; Sairafi D; Hassan Z; Mattsson J; Omazic B; Barkholt L; Ringdén O
Transplantation; 2006 Oct; 82(7):913-9. PubMed ID: 17038906
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
9. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R; Nademanee A; Ruel N; Smith E; Krishnan A; Popplewell L; Zain J; Patane K; Kogut N; Nakamura R; Sarkodee-Adoo C; Forman SJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
Schetelig J; Oswald O; Steuer N; Radonic A; Thulke S; Held TK; Oertel J; Nitsche A; Siegert W
Bone Marrow Transplant; 2003 Oct; 32(7):695-701. PubMed ID: 13130317
[TBL] [Abstract][Full Text] [Related]
11. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
13. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
[TBL] [Abstract][Full Text] [Related]
14. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
[TBL] [Abstract][Full Text] [Related]
15. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.
Matthes-Martin S; Lion T; Aberle SW; Fritsch G; Lawitschka A; Bittner B; Frommlet F; Gadner H; Peters C
Bone Marrow Transplant; 2003 May; 31(9):803-8. PubMed ID: 12732888
[TBL] [Abstract][Full Text] [Related]
16. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
17. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
Ozdemir E; Saliba RM; Champlin RE; Couriel DR; Giralt SA; de Lima M; Khouri IF; Hosing C; Kornblau SM; Anderlini P; Shpall EJ; Qazilbash MH; Molldrem JJ; Chemaly RF; Komanduri KV
Bone Marrow Transplant; 2007 Jul; 40(2):125-36. PubMed ID: 17530009
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
19. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
Bacigalupo A; Tedone E; Sanna MA; Moro F; Van Lint MT; Grazi G; Balestreri M; Frassoni F; Occhini D; Gualandi F
Haematologica; 1992; 77(6):507-13. PubMed ID: 1337746
[TBL] [Abstract][Full Text] [Related]
20. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
